Stephen K. Brannan - 30 Dec 2021 Form 4 Insider Report for Karuna Therapeutics, Inc.

Role
Chief Medical Officer
Signature
/s/ Troy Ignelzi, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
30 Dec 2021
Net transactions value
-$926,023
Form type
4
Filing time
03 Jan 2022, 18:06:52 UTC
Previous filing
02 Dec 2021
Next filing
02 Feb 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KRTX Common Stock Options Exercise $13,625 +2,500 +12% $5.45* 22,500 03 Jan 2022 Direct
transaction KRTX Common Stock Options Exercise $71,098 +7,728 +34% $9.20* 30,228 03 Jan 2022 Direct
transaction KRTX Common Stock Sale $1,010,745 -7,728 -26% $130.79 22,500 03 Jan 2022 Direct F1
transaction KRTX Common Stock Gift $0 -15,000 -67% $0.000000 7,500 30 Dec 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KRTX Option (right to buy) Options Exercise $0 -2,500 -5.4% $0.000000 43,704 03 Jan 2022 Common Stock 2,500 $5.45 Direct F2
transaction KRTX Option (right to buy) Options Exercise $0 -7,728 -10% $0.000000 67,717 03 Jan 2022 Common Stock 7,728 $9.20 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 1, 2021.
F2 This option vested as to 25% of the shares on the first anniversary of the vesting commencement date of March 1, 2017, with additional vesting as to 12.5% of the shares underlying the option award at the end of each six month period thereafter.
F3 This option vests as to 12.5% of the shares underlying the option award on each six month anniversary following the vesting commencement date of March 21, 2019.